{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:21:48Z","timestamp":1764174108895},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T00:00:00Z","timestamp":1421020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T00:00:00Z","timestamp":1421020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1038\/bmt.2014.301","type":"journal-article","created":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T19:19:38Z","timestamp":1421090378000},"page":"599-600","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ponatinib given for advanced leukemia relapse after allo-SCT"],"prefix":"10.1038","volume":"50","author":[{"given":"K","family":"Hirschbuehl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Rank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H R","family":"Slawik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Schlimok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H J","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ch","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,12]]},"reference":[{"key":"BFbmt2014301_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2013.08.012","volume":"20","author":"M de Lima","year":"2014","unstructured":"de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant 2014; 20: 4\u201313.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014301_CR2","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1158\/1078-0432.CCR-03-0580","volume":"10","author":"DJ DeAngelo","year":"2004","unstructured":"DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004; 10: 5065\u20135071.","journal-title":"Clin Cancer Res"},{"key":"BFbmt2014301_CR3","doi-asserted-by":"publisher","first-page":"7583","DOI":"10.1200\/JCO.2005.01.3110","volume":"23","author":"G Hess","year":"2005","unstructured":"Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005; 23: 7583\u20137593.","journal-title":"J Clin Oncol"},{"key":"BFbmt2014301_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.bbmt.2009.08.019","volume":"16","author":"E Klyuchnikov","year":"2010","unstructured":"Klyuchnikov E, Kroger N, Brummendorf TH, Wiedemann B, Zander AR, Bacher U . Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML). Biol Blood Marrow Transplant 2010; 16: 301\u2013310.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014301_CR5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783\u20131796.","journal-title":"N Engl J Med"},{"key":"BFbmt2014301_CR6","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, Muller MC, Saglio G, Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172\u20132175.","journal-title":"Leukemia"},{"key":"BFbmt2014301_CR7","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367: 2075\u20132088.","journal-title":"N Engl J Med"},{"key":"BFbmt2014301_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMc1315234","volume":"370","author":"A Quintas-Cardama","year":"2014","unstructured":"Quintas-Cardama A . Ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2014; 370: 577.","journal-title":"N Engl J Med"},{"key":"BFbmt2014301_CR9","doi-asserted-by":"publisher","first-page":"7084","DOI":"10.1200\/jco.2014.32.15_suppl.7084","volume":"32","author":"A Hochhaus","year":"2014","unstructured":"Hochhaus A, Pinilla-Ibarz J, Kim D-W, Le Coutre PD, Paquette R, Chuah C et al. Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias. J Clin Oncol 2014; 32: 7084.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2014301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2014301","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2014301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T18:08:03Z","timestamp":1648058883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2014301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,12]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["BFbmt2014301"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2014.301","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,12]]},"assertion":[{"value":"12 January 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}